pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2861Research ArticleОБЗОРЫREVIEWКлиническая эффективность формотерола при отсутствии ответа на сальметерокClinical efficiency of formoterol when there is no response to salmeterolКоттакисД.KottakisJ.
Horsham
ВудсР.WoodsR.
Switzerland
Ле ГроссВ.Le GrossV.
Rueil Malmaison
Делла СьоппаД.Della CioppaG.
Horsham
Novartis Respiratory Reseach CentreUnited KingdomNovartis Pharma AG BaselSwitzerlandNovartis Pharma SAFrance2001301220010498102Copyright © Коттакис Д., Вудс Р., Ле Гросс В., Делла Сьоппа Д., 20012001Коттакис Д., Вудс Р., Ле Гросс В., Делла Сьоппа Д.Kottakis J., Woods R., Le Gross V., Della Cioppa G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2861
.
.
ReferencesCampbell L.M., Anderson J., Paraschchak M.R. et al. A comparison of the efficacy of long-acting p2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group. Respir. Med. 1999; 93: 236—244.Campbell L.M., Anderson J., Paraschchak M.R. et al. A comparison of the efficacy of long-acting p2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group. Respir. Med. 1999; 93: 236—244.Vervloet D., Ekstrom Т., Pela R. et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Ibid. 1998; 92: 836—842.Vervloet D., Ekstrom Т., Pela R. et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Ibid. 1998; 92: 836—842.Redington A.E., Rees P.J. Long-acting inhaled p2-agonists in the management of asthma: recent advances and current recommendations. Int. J. Clin. Pract. 1998; 52(7): 482—486.Redington A.E., Rees P.J. Long-acting inhaled p2-agonists in the management of asthma: recent advances and current recommendations. Int. J. Clin. Pract. 1998; 52(7): 482—486.Wallin A., Sandstorm Т., Rosenhall L., Melander B. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611—614.Wallin A., Sandstorm Т., Rosenhall L., Melander B. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611—614.van Noord J.A., S treets J.J., Raaijmakers S.A.M. et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 1996; 9: 1684—1688.van Noord J.A., S treets J.J., Raaijmakers S.A.M. et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur. Respir. J. 1996; 9: 1684—1688.Palmqvist М., Persson G., L azer L. et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Ibid. 1997; 10: 2484—2489.Palmqvist М., Persson G., L azer L. et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Ibid. 1997; 10: 2484—2489.Ulrik C.S., Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Ibid. 1994; 7: 1003—1005.Ulrik C.S., Kok-Jensen A. Different bronchodilating effect of salmeterol and formoterol in an adult asthmatic. Ibid. 1994; 7: 1003—1005.Bartuschka B., Querfert H., Ortland C. et al. Formoterol Turbuhaler shows bronchodilating efficacy in patients not responding to salmeterol diskus. Am. J. Respir. Crit. Care Med. 2000; 161 (3): A 190.Bartuschka B., Querfert H., Ortland C. et al. Formoterol Turbuhaler shows bronchodilating efficacy in patients not responding to salmeterol diskus. Am. J. Respir. Crit. Care Med. 2000; 161 (3): A 190.Noppen M., Vincken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration 2000; 67 (1): 112—113.Noppen M., Vincken W. Bronchodilating effect of formoterol but not of salmeterol in two asthmatic patients. Respiration 2000; 67 (1): 112—113.Bousquet J., Meziane H., Le Gros V., Bourdeux I. Efficacite du formoterol chez des asthmatiques equilibres de facon non optimale par le salmeterol. Rev. Mai. Respir. 2001; 18 (1): S31.Bousquet J., Meziane H., Le Gros V., Bourdeux I. Efficacite du formoterol chez des asthmatiques equilibres de facon non optimale par le salmeterol. Rev. Mai. Respir. 2001; 18 (1): S31.Andersen G.P. Formoterol: pharmacology, molecular basis of antagonism, and mechanism of long duration of a highly potent and selective p9-adrenoceptor agonist bronchodilator. Life Sci. 1993; 52: 2145—2160.Andersen G.P. Formoterol: pharmacology, molecular basis of antagonism, and mechanism of long duration of a highly potent and selective p9-adrenoceptor agonist bronchodilator. Life Sci. 1993; 52: 2145—2160.Green S.A., Spasoff A.P., Coleman R.A. et al. Sustained activation of a G-protein-coupled receptor via anchored agonist binding. J. Biol. Chem. 1996; 271 (39): 24029—24036.Green S.A., Spasoff A.P., Coleman R.A. et al. Sustained activation of a G-protein-coupled receptor via anchored agonist binding. J. Biol. Chem. 1996; 271 (39): 24029—24036.Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.Palmqvist M., Ibsen T., Mellen A., Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999; 160: 244—249.Molimard M., Naline E., Zhang Y. et al. Long- and short-acting p2-adrenoceptor agonists interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.Molimard M., Naline E., Zhang Y. et al. Long- and short-acting p2-adrenoceptor agonists interactions in human contracted bronchi. Eur. Respir. J. 1998; 11: 583—588.Van Veen A., Weller F.R., Wierenga E.A. et al. Regular use of long-acting p2-adrenoceptor agonists attenuates the bronchoprotective efficacy of short-acting p2-adrenoceptor agonists in asthma. Br. J. Clin. Pharmacol. 2000; 50: 485P—499P.Van Veen A., Weller F.R., Wierenga E.A. et al. Regular use of long-acting p2-adrenoceptor agonists attenuates the bronchoprotective efficacy of short-acting p2-adrenoceptor agonists in asthma. Br. J. Clin. Pharmacol. 2000; 50: 485P—499P.Hancox R.J., Sears M.R., Taylor D.R. Polymorphism of the p2-adrenoceptor and the response to long term P2-agonist therapy in asthma. Eur. Respir. J. 1998; 11: 589—593.Hancox R.J., Sears M.R., Taylor D.R. Polymorphism of the p2-adrenoceptor and the response to long term P2-agonist therapy in asthma. Eur. Respir. J. 1998; 11: 589—593.Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337 (20): 1405—1411.Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N. Engl. J. Med. 1997; 337 (20): 1405—1411.Bourns D., Bachlitzanakis N., Kottakis J. et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur. Respir. J. 1999; 14 (3): 627—632.Bourns D., Bachlitzanakis N., Kottakis J. et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur. Respir. J. 1999; 14 (3): 627—632.Greening A. P., Ind P.W., Northfie ld M., S haw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen&Hanburys UK Study Group. Lancet 1994; 344: 219—224.Greening A. P., Ind P.W., Northfie ld M., S haw G. Added salmeterol versus higher dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen&Hanburys UK Study Group. Lancet 1994; 344: 219—224.Hancox R.J., Stevens D.A., Adcock A. M. et al. Effects of inhaled p-agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999; 54: 488—492.Hancox R.J., Stevens D.A., Adcock A. M. et al. Effects of inhaled p-agonist and corticosteroid treatment on nuclear transcription factors in bronchial mucosa in asthma. Thorax 1999; 54: 488—492.Taylor D.R., Hancox R.J. Interactions between corticosteroids and p-agonists. Ibid. 2000; 55: 596—602.Taylor D.R., Hancox R.J. Interactions between corticosteroids and p-agonists. Ibid. 2000; 55: 596—602.Scarceriaux V., Pelaprat D., Forgez P. et al. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. Endocrinology 1995; 136: 2554—2560.Scarceriaux V., Pelaprat D., Forgez P. et al. Effects of dexamethasone and forskolin on neurotensin production in rat hypothalamic cultures. Endocrinology 1995; 136: 2554—2560.Peters M.J., Adcock I.M., Brown C.R. et al. p-adrenoceptor agonists interfere with glucorticoid receptor DNA binding in rat lung. Eur. J. Pharmacol. 1995; 289: 275—281.Peters M.J., Adcock I.M., Brown C.R. et al. p-adrenoceptor agonists interfere with glucorticoid receptor DNA binding in rat lung. Eur. J. Pharmacol. 1995; 289: 275—281.
The authors declare that there are no conflicts of interest present.